Cargando…

Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review

Background: TNFα inhibitors are regularly used to treat autoimmune diseases. Tuberculosis (TB) and viral hepatitis B are considered potential infectious complications, and screening and surveillance are therefore recommended. Current guidelines do not take into account regional differences in endemi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jahnich, Nina, Arkwright, Peter D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894886/ https://www.ncbi.nlm.nih.gov/pubmed/36744250 http://dx.doi.org/10.3389/fphar.2023.1046306

Ejemplares similares

Identification of Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor in Rheumatoid Arthritis Using Network Pharmacology and Molecular Docking
por: Bai, Liang Liang, et al.
Publicado: (2021)

Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries
por: Inotai, András, et al.
Publicado: (2020)

Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: A meta-analysis of randomized, placebo-controlled trials
por: Feng, Haihuan, et al.
Publicado: (2023)

Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets’ Disease-Associated Uveitis: A Systematic Review and Meta-Analysis
por: Hu, Yunwei, et al.
Publicado: (2020)

Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis
Publicado: (1994)

Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: An assessment using the FDA adverse event reporting system
por: Onda, Kenji, et al.
Publicado: (2023)

Tumor Necrosis Factor-Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis: A Systematic Review
por: Nair, Shaalina, et al.
Publicado: (2022)

Combination of Wogonin and Artesunate Exhibits Synergistic anti-Hepatocellular Carcinoma Effect by Increasing DNA-Damage-Inducible Alpha, Tumor Necrosis Factor α and Tumor Necrosis Factor Receptor-Associated Factor 3-mediated Apoptosis
por: Chen, Minting, et al.
Publicado: (2021)

Computational analysis to investigate the anti-rheumatic potential of plant-based small molecule inhibitor targeting tumor necrosis factor α
por: Rehman, Sanaya, et al.
Publicado: (2023)

A human inhibitor of tumor necrosis factor alpha
Publicado: (1988)

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis
por: Callejas-Rubio, José Luis, et al.
Publicado: (2008)

Anthraquinone Emodin Inhibits Tumor Necrosis Factor Alpha-Induced Calcification of Human Aortic Valve Interstitial Cells via the NF-κB Pathway
por: Xu, Kang, et al.
Publicado: (2018)

Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice
por: Chen, Yi-Hsing, et al.
Publicado: (2018)

Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies
por: Ferraro, Sara, et al.
Publicado: (2019)

The adverse drug reactions to tumor necrosis factor alpha inhibitor
por: Park, Hye-Kyung, et al.
Publicado: (2014)

Tumor Necrosis Factor Alpha Inhibitor-Induced Acute Pancreatitis
por: Werlang, Monia E., et al.
Publicado: (2017)

Anti-tumour necrosis factor-alpha agent therapy, compared with conventional therapy, reduces the relapse of uveitis in patients with behçet’s disease: A systematic review of controlled trials
por: Zhou, Xinwei, et al.
Publicado: (2022)

Differential Effects of Inhibitor Combinations on Lysophosphatidic Acid-Mediated Chemokine Secretion in Unprimed and Tumor Necrosis Factor-α-Primed Synovial Fibroblasts
por: Hui, Weili, et al.
Publicado: (2017)

Effectiveness of Subcutaneous Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Real-World Prospective Observational Cohort Study in China
por: Ji, Xiaojian, et al.
Publicado: (2019)

Tumor Necrosis Factor-Alpha Induced by Hepatitis B Virus Core Mediating the Immune Response for Hepatitis B Viral Clearance in Mice Model
por: Tzeng, Horng-Tay, et al.
Publicado: (2014)

Tumor Necrosis Factor-Alpha Gene Promoter Region Polymorphism and the Risk of Coronary Heart Disease
por: Asifa, Gul Zareen, et al.
Publicado: (2013)

In Silico Discovery of Plant-Origin Natural Product Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
por: Melagraki, Georgia, et al.
Publicado: (2018)

Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
por: Kucharz, Eugeniusz Józef, et al.
Publicado: (2021)

Pulmonary and Peritoneal Tuberculosis Associated with Tumor Necrosis Factor-Alpha Inhibitor Use: A Case Report and Review of the Literature
por: Tipirneni, Niharika, et al.
Publicado: (2012)

Optimisation of alpha-amylase inhibitor production in solid state fermentation
por: Fatoki, O. A., et al.
Publicado: (2023)

Genetically proxied inhibition of tumor necrosis factor and the risk of colorectal cancer: A drug-target mendelian randomization study
por: Chen, Min, et al.
Publicado: (2022)

Production of tumor necrosis factor-alpha by alveolar macrophages from patients with pulmonary tuberculosis.
por: Kim, S. J., et al.
Publicado: (1991)

Familial secondary hyperhidrosis associated with tumor necrosis factor–alpha inhibitor treatment
por: Ikediobi, Ogechi, et al.
Publicado: (2015)

The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis
por: Lee, Suhwan, et al.
Publicado: (2019)

Phytochemicals as inhibitors of tumor necrosis factor alpha and neuroinflammatory responses in neurodegenerative diseases
por: Zahedipour, Fatemeh, et al.
Publicado: (2022)

Mechanisms of Tumor Necrosis Factor-Alpha Inhibitor-Induced Systemic Lupus Erythematosus
por: Yen, Chung-Yang, et al.
Publicado: (2022)

Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
por: Pagnini, Cristiano, et al.
Publicado: (2019)

Alpha-Glucosidase Inhibitors Alter Gut Microbiota and Ameliorate Collagen-Induced Arthritis
por: Zhang, Lingshu, et al.
Publicado: (2020)

Genetic Polymorphism of Tumor Necrosis Factor-Alpha, Interferon-Gamma and Interleukin-10 and Association With Risk of Mycobacterium Tuberculosis Infection
por: Adane, Gashaw, et al.
Publicado: (2021)

Mendelian randomization analysis identified tumor necrosis factor as being associated with severe COVID-19
por: Song, Hongfei, et al.
Publicado: (2023)

Diazepam ameliorated myocardial ischemia-reperfusion injury via inhibition of C-C chemokine receptor type 2/tumor necrosis factor-alpha/interleukins and Bcl-2-associated X protein/caspase-3 pathways in experimental rats
por: JIANG, Tingting, et al.
Publicado: (2021)

Tumor Necrosis Factor Alpha -308G/A Gene Polymorphisms Combined with Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio Predicts the Efficacy and Safety of Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Arthritis
por: Wang, Ziran, et al.
Publicado: (2022)

Targeting Mycobacterium tuberculosis Tumor Necrosis Factor Alpha-Downregulating Genes for the Development of Antituberculous Vaccines
por: Olsen, Aaron, et al.
Publicado: (2016)

A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn’s Disease
por: Nie, Kai, et al.
Publicado: (2022)

Appearance of ANCA – associated vasculitis under Tumor necrosis factor-alpha inhibitors treatment
por: Reitblat, Tatiana, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_retfo8bdlefqbps4is555kdds6